

**Anterior Segment Surgery Update**

**Saturday, March 16, 2024**

*Wills Eye Auditorium*

**[Conference Description:](https://attendee.gotowebinar.com/register/3787369390277133912%22%20Click%20Here%20to%20Register%20for%20the%20Livestream%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

[Click Here to Register for the Livestream!](https://attendee.gotowebinar.com/register/3787369390277133912%22%20Click%20Here%20to%20Register%20for%20the%20Livestream%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

[With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.](https://attendee.gotowebinar.com/register/3787369390277133912%22%20Click%20Here%20to%20Register%20for%20the%20Livestream%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

**At the conclusion of the course, participants should be able to:**

1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of glaucoma.

2 Identify basic and clinical vision research that can be transformed into improved clinical care.

3 Assess the role of new technologies in the surgical treatment of the anterior segment including cataracts and glaucoma.

4 Describe factors that impact the effective delivery of the highest quality eye care for the public

5 Identify clinical, scientific, and ethical issues confronting the profession

6 Obtain information and tools through multiple facets to help ophthalmologists deliver efficient and high-quality care

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this Live Activity for a maximum of 4.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Nothing to disclose - 03/06/2024 |
| Marisa Schoen, MD | Faculty | Nothing to disclose - 03/05/2024 |
| Reza Razeghinejad, MD | Faculty | Grant or research support-Olleyes|Grant or research support-Equinox (Relationship has ended) - 02/29/2024 |
| Beeran Meghpara, MD | Faculty | Consulting Fee-Sun Pharmaceutical Industries|Consulting Fee-Glaukos Corporation|Consulting Fee-Johnson & Johnson|Consulting Fee-Santen Pharmaceuticals|Consulting Fee-Kala Pharmaceuticals|Consulting Fee-OCULUS Surgical, Inc.|Consulting Fee-Allergan|Consulting Fee-Sight Sciences|Consulting Fee-Dompé |Consulting Fee-Zeiss|Consulting Fee-Bio-Tissue|Consulting Fee-Tarsus|Consulting Fee-Thea|Consulting Fee-Centricity|Consulting Fee-Orasis|Consulting Fee-WL Gore & Associates - 02/06/2024 |
| Brenton D. Finklea, MD | Faculty | Consulting Fee-Alcon - 03/14/2024 |
| Douglas Wisner, MD | Faculty, Planner | Advisor-Zeiss|Advisor-Haag-Streit - 03/06/2024 |
| Brandon D. Ayres, MD | Faculty, Planner | Consulting Fee-Alcon|Consulting Fee-Allergan|Consulting Fee-Bausch + Lomb|Consulting Fee-Sun Pharmaceutical Industries|Consulting Fee-Novartis|Consulting Fee-Dompé  - 04/20/2023 |
| Sadeer B. Hannush, MD | Faculty | Consulting Fee-Kowa, Inc - 03/08/2024 |
| Mark F Pyfer, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Johnson & Johnson|Paid consultant-Johnson & Johnson|Independent Contractor (included contracted research)-Sight Sciences (Relationship has ended)|Speakers Bureau-Sight Sciences|Speakers Bureau-Rayner Surgical|Independent Contractor (included contracted research)-Tarsus (Relationship has ended) - 12/10/2023 |
| Elizabeth Dale, MD | Faculty | Consulting Fee-Sight Sciences - 01/12/2024 |
| Melissa Sieber, MD | Faculty, Peer Reviewer | Nothing to disclose - 03/14/2024 |
| Brett Weinstock, MD | Faculty, Peer Reviewer | Nothing to disclose - 03/07/2024 |
| John C Anhalt, MD | Faculty | Nothing to disclose - 04/21/2023 |
| Walter Harris, MD | Faculty | Nothing to disclose - 04/21/2023 |
| Nicholas Hadjokas, MD | Faculty | Nothing to disclose - 03/08/2024 |
| Sarah Michelson, MD | Faculty, Peer Reviewer | Nothing to disclose - 03/05/2024 |
| Jeff McMahon, MD | Faculty, Peer Reviewer | Nothing to disclose - 04/17/2023 |
| Dilru C Amarasekera, MD | Faculty | Nothing to disclose - 01/08/2024 |

